Scholars Central

Research articlePublished 30 Sep 2014

Molecular docking studies of lichen metabolites as malarial protein inhibitors: Plasmepsin II protease and dihydro folate reductase

Authors: E. Susithra, S. Meena, D. Chamundeeswari, Rajasekhar Chekkara, Ethiraj Varalakshmi

Journal of Chemical and Pharmaceutical Research

Volume 6 · Issue 9 · Pages 501–512

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Plasmepsin II (PL II), an aspartyl protease inhibitor of P. falciparum, plays a key role in the haemoglobin degradation inside the food vacuole. Besides, dihydrofolate reductase (DHFR), a small enzyme that plays a critical role in the building of DNA and other processes, is found to be involved in the reproduction of the parasites, P. falciparum and P. vivax. Recently more focus has been arrived in the treatment and cure of malaria through inhibition of these key enzymes, PL II protease and DHFR. The main aim of the present study is to find out the binding mode and hydrogen bond interactions of the lichen metabolites; depsides viz. atranorin (ATR) & lecanoric acid (LA), depsidone, salazinic acid (SA) and dibenzofuran, usnic acid (USA) derivatives with PL II protease and DHFR proteins through molecular docking simulations using glide module v5.5 (Schrodinger suite 2009) by flexible docking method. The docking results indicate that the dibenzofuran USA derivatives are showing impressive hydrogen bond and hydrophobic interactions with PL II protease, whereas the depsidone, SA shows satisfactory interactions and the depsides namely, ATR and LA with least interactions. With respect to the DHFR, depsides; ATR and LA are showing effective H-bond interactions with the DHFR protein active sites of the two species in different docking grids. Further, SA and USA derivatives are showing flat interactions with the active residues of the DHFR protein. From the above results, it is clearly evident that further studies can be attempted in designing similar such structure-based novel molecules with PL II and DHFR inhibitory activity.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Chemical and Pharmaceutical Research
  • SubjectPharmaceutical Sciences
  • SubjectChemistry
  • BylineArticles whose byline prints “E. Susithra”
  • BylineArticles whose byline prints “S. Meena”
  • BylineArticles whose byline prints “D. Chamundeeswari”
  • BylineArticles whose byline prints “Rajasekhar Chekkara”
  • BylineArticles whose byline prints “Ethiraj Varalakshmi”